Brief: 23Andme Therapeutics Announces Positive In Vivo Results For 23Me-01473, A Dual-Mechanism Ulbp6-Targeting Antibody Currently In A Phase 1 Trial
15/09/2024 08:06
23andMe Holding Co. ME.O :
* 23ANDME THERAPEUTICS ANNOUNCES POSITIVE IN VIVO RESULTS
FOR
23ME-01473, A DUAL-MECHANISM ULBP6-TARGETING ANTIBODY CURRENTLY
IN A PHASE 1 TRIAL
Source text for Eikon: ID:nGNX5H5YqK
Further company coverage: ME.O
Recent news on Chrome Holding Co
See all newsBrief: Chrome Holding Co Enters Into Stock Purchase Agreement With Bambu Ventures
23andMe seeks approval of larger, $50 million data breach settlement
Brief: 23andMe Holding Co Changes Name to Chrome Holding Co
Brief: 23andMe Holding Says Debtors Repay All Outstanding Indebtedness, Terminate Loan Agreement
founder